Carlene Todd

The Canadian market access landscape is rapidly evolving due to shifting government policies, payer dynamics, and the complexity of biopharmaceutical innovation. This session will explore key trends, including pricing and policy changes, data-driven decision-making, new funding models, equity in access and digital health solutions, while highlighting opportunities for industry stakeholder collaboration to enhance patient access.

• Impact of Pricing and Policy Changes within Canada/US, Globally,  

• Navigating evidence demands for high-cost therapies and rare disease treatments, leveraging real-world evidence,  

• health outcomes data, and patient-reported outcomes to meet payer evidence demands.  

• Data-Driven Decision Making and the growing importance of economic modeling and burden-of-illness studies ,  

• Equity of access and digital health solutions and value-based reimbursement models exploring opportunities for collaboration between industry stakeholders to improve patient access